Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Operating Expenses (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Operating Expenses for 13 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 81.69% to $1.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.1 billion through Dec 2025, up 109.08% year-over-year, with the annual reading at $1.3 billion for FY2025, 85.62% up from the prior year.
  • Operating Expenses for Q4 2025 was $1.2 billion at Madrigal Pharmaceuticals, up from $401.2 million in the prior quarter.
  • The five-year high for Operating Expenses was $1.2 billion in Q4 2025, with the low at $2.2 million in Q3 2024.
  • Average Operating Expenses over 5 years is $201.4 million, with a median of $85.9 million recorded in 2022.
  • The sharpest move saw Operating Expenses plummeted 97.82% in 2024, then skyrocketed 18545.12% in 2025.
  • Over 5 years, Operating Expenses stood at $64.6 million in 2021, then soared by 32.04% to $85.3 million in 2022, then soared by 37.37% to $117.2 million in 2023, then soared by 476.24% to $675.2 million in 2024, then surged by 81.69% to $1.2 billion in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $1.2 billion, $401.2 million, and $260.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.